Table of Contents		

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 22, 2009

TASER International, Inc.

(Exact name of registrant as specified in its charter)

	Delaware	001-16391	86-0741227		
(State or other jurisdiction (Commission File Number) (IRS Employer Identification					
	of incorporation)				
	17800 N. 85th St.				
	Scottsdale, Arizona		85255		
	(Address of principal executive o	ffices)	(Zip Code)		
		lephone number, including area code: (a	<u> </u>		
	eck the appropriate box below if the Form er any of the following provisions:	8-K filing is intended to simultaneously	y satisfy the filing obligation of the registrant		
	Written communications pursuant to Ru	lle 425 under the Securities Act (17 CFF	R 230.425)		
	Soliciting material pursuant to Rule 14a	-12 under the Exchange Act (17 CFR 24	40.14a-12)		
	Pre-commencement communications pu	ursuant to Rule 14d-2(b) under the Exch	ange Act (17 CFR 240.14d-2(b))		
	Pre-commencement communications pu	ursuant to Rule 13e-4(c) under the Exch	ange Act (17 CFR 240.13e-4(c))		

TABLE OF CONTENTS

Item 2.02 Results of Operations and Financial Condition	2
Item 9.01 Financial Statements and Exhibits	2
SIGNATURE	3
Exhibit 99.1	

Table of Contents

Item 2.02 Results of Operations and Financial Condition

The information pursuant to Item 2.02 in this report on Form 8-K is being furnished as contemplated by General Instruction B(2) to Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

On October 22, 2009, TASER International, Inc. (the "Company") issued a press release regarding the Company's financial results for its third quarter ended September 30, 2009. The full text of the press release, together with the unaudited consolidated statements of operations, balance sheets, selected statements of cashflow information and reconciliations of GAAP to non-GAAP financial measures are attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

- (d) Exhibits.
 - 99.1 Text of press Release dated October 22, 2009 titled "TASER International, Inc. Reports Third Quarter 2009 Results".

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 22, 2009 TASER International, Inc.

By: /s/ DANIEL BEHRENDT

Daniel Behrendt Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number	Description of Document
99.1	Text of press Release dated October 22, 2009 titled "TASER International, Inc. Reports Third Quarter 2009
	Results".

CONTACT: Dan Behrendt

Chief Financial Officer TASER International, Inc.

(480) 905-2000

TASER International Reports Third Quarter 2009 Results

Reports Strong Adjusted Revenue Growth of 17%, Cash Position Remains Solid

SCOTTSDALE, Ariz., October 22, 2009 — TASER International, Inc. (NASDAQ: TASR), a leading provider of technology solutions and the market leader in electronic control devices (ECDs) today reported financial results for the third quarter ended September 30, 2009.

During the third quarter, the Company announced a trade-in program to enable agencies to easily upgrade to the newly announced semi-automatic TASER X3. As required by applicable accounting principles, the Company deferred \$3.5 million of revenue until the respective trade-in occurs or the trade-in program expires at December 31, 2009. This temporary deferral significantly reduces GAAP reported net sales as compared to adjusted revenue for product shipments. Additionally, all the product costs associated with the sale were recognized at the time of delivery to the customer. In order to simplify comparison to prior periods, the Company will discuss both its GAAP and its adjusted (non-GAAP) results assuming this revenue was not deferred.

Q3 Financial Summary:

- Adjusted revenues for the third quarter of 2009 were \$26.8 million, an increase of \$4.0 million or 17% over the same quarter of the prior year. For the first nine months of 2009, adjusted revenues were \$73.2 million, an increase of \$6.8 million or 10.0% over the first nine months of 2008. Adjusted revenues exclude the impact of a \$3.5 million revenue deferral related to the X26 to X3 trade-in credit program, the balance of which is expected to be recognized as revenue when the trade-in occurs or the offer expires at December 31, 2009. On a GAAP basis, net sales for the third quarter and first nine months of 2009 were \$23.3 million and \$69.7 million, respectively. Net sales for the third quarter and first nine months of 2008 were \$22.9 million and \$66.4 million respectively.
- Adjusted gross margin, which excludes the impact of the X26 to X3 trade-in credit program, improved to 62.5% in the third quarter of 2009, compared to 60.8% in the third quarter of 2008. On a GAAP basis, gross margin for the third quarter was 56.9%, compared to 60.8% in the third quarter of 2008.
- Research and development expenses of \$6.7 million increased by \$3.3 million, or 100%, in the third quarter of 2009 compared to the same period in 2008. The increase was driven primarily by ongoing, intensive development efforts to bring multiple new products to market including the TASER ® X3TM, TASER ® AXONTM and EVIDENCE.COM. The accelerated research and development costs were associated with the simultaneous launch of two major product lines in the quarter: the new TASER X3 and the AXON Tactical Computer. The Company expects R&D costs to return to more normal levels in the fourth quarter.
- Adjusted operating income for the third quarter of 2009, which excludes the X26 to X3 trade-in revenue deferral, stock-based compensation charges, depreciation and amortization and litigation judgment expense, was \$0.6 million compared to \$2.8 million for the third quarter of 2008. GAAP loss from operations was \$(4.8) million for the third quarter of 2009 compared to income from operations of \$1.5 million for the same period in the prior year.

- Net loss and diluted loss per share for the third quarter of 2009 were \$(3.2) million and \$(0.05), respectively.
- The Company generated \$5.5 million in cash from operating activities in the first nine months of 2009 with ending cash and cash equivalents of \$45.4 million and no debt.

Significant events in the third quarter of 2009 include the following:

- 1. International sales represented 19% of net sales and 16% of adjusted revenues for the third quarter (including the impact of revenue deferred for GAAP purposes relating to the X26 to X3 trade-in program). Significant shipments during the third quarter included follow-on orders for 1962 TASER ® X26TM ECDs, 1962 TASER CAMsTM and related accessories to Australia.
- 2. Sales to our Federal and military customers significantly increased during the quarter, partly due to the first order for TASER ® X26TM ECDs and cartridges shipped under an indefinite delivery, indefinite quantity (IDIQ) contract from the U.S. Customs and Border Protection (CBP).
- 3. On July 27, 2009, the next generation TASER ® X3TM ECD was unveiled at the annual TASER Conference. The TASER X3 is capable of firing three cartridges without reloading and uses a Pulse Calibration SystemTM to constantly monitor and calibrate electrical output to provide more consistent effects on the target.
- 4. Six (6) product liability suits were dismissed during the quarter, representing at the end of the quarter a total of ninety-six (96) wrongful death or injury suits that have been dismissed or judgment entered in favor of the Company.

"I am extremely proud of our team, which was able to turn in one of the strongest sales quarters in our Company's history despite the challenging economic environment," said Rick Smith, CEO of TASER International. "In addition to the strong sales for our existing products, our new AXON and EVIDENCE.com products continue to receive widespread praise from the law enforcement community. Both products recently received top industry awards at the International Association of Chiefs of Police Conference in the law enforcement computer and software categories, which is a great start as we prepare to bring these products to market in 2010. The investments we have made in these transformative products have positioned the Company to build on our reputation as not only the leading name in ECDs, but a pioneer in defense-oriented technologies and software services as well."

The Company will host its third quarter 2009 earnings conference call on Thursday, October 22, 2009 at 11:00 a.m. ET. The conference call is available via web cast and can be accessed on the "Investor Relations" page at www.TASER.com. To access the teleconference, please dial: 1-866-700-7477 or 1-617-213-8440 for international callers. The pass code is 26406262 for both numbers.

Non-GAAP Measures

To supplement the Company's Statements of Operations presented in accordance with GAAP, we are presenting non-GAAP measures of certain components of financial performance. We have presented these measures for our investors to be better able to compare our current results with those of previous periods and have shown a reconciliation of GAAP to the non-GAAP financial measures in the tables at the end of this release. These non-GAAP measures include: (1) for adjusted revenue and adjusted gross margin, the impact of sales that were made during the third quarter pursuant to our X26 to X3 trade-in credit program that for GAAP purposes the resulting revenues were deferred until the sooner of when the offer is redeemed or the trade-in upgrade period expires, which will be no later than December 31, 2009 ("deferred sales") and (2) for income (loss) from operations, the impact of deferred sales, non-cash stock-based compensation expense, depreciation and amortization and litigation judgment expense. We use these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain expenses and expenditures that may not be indicative of our "recurring core business operating results," meaning our operating performance excluding non-cash charges, such as stock-based compensation, depreciation and amortization and other discrete charges that are infrequent in nature. Additionally, because the temporary non-cash revenue deferral for the X26 to X3 trade-in credit program significantly reduces GAAP reported net sales as compared to adjusted revenue for product shipments, and whereas all the product costs associated with the sale were recognized at the time of delivery to the customer, the presentation of adjusted results assuming this revenue was not deferred simplifies the comparison to prior periods. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to our historical performance and liquidity.

Caution on Use of Non-GAAP Measures

As noted previously, these non-GAAP financial measures are not consistent with GAAP because they do not reflect the deferral of revenue and the impact of other non-cash charges.

Management believes investors will benefit from greater transparency in referring to these non-GAAP financial measures when assessing the Company's operating results, as well as when forecasting and analyzing future periods. However, management recognizes that:

- these non-GAAP financial measures are limited in their usefulness and should be considered only as a supplement to the Company's GAAP financial measures;
- these non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Company's GAAP financial measures;
- these non-GAAP financial measures should not be considered to be superior to the Company's GAAP financial measures;
- these non-GAAP financial measures were not prepared in accordance with GAAP and investors should not assume that the non-GAAP financial measures presented in this earnings release were prepared under a comprehensive set of rules or principles.

Further, these non-GAAP financial measures may be unique to the Company, as they may be different from non-GAAP financial measures used by other companies. As such, this presentation of non-GAAP financial measures may not enhance the comparability of the Company's results to the results of other companies.

A reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure or measures appears at the end of this press release.

About TASER International, Inc. (TASR):

TASER International's products protect life, providing advanced Electronic Control Devices for use in the law enforcement, medical, military, corrections, professional security, and personal protection markets. TASER ® devices use proprietary technology to incapacitate dangerous, combative, or high-risk subjects who pose a risk to law enforcement officers, innocent citizens, or themselves in a manner that is generally recognized as a safer alternative to other uses of force. TASER technology protects life, and the use of TASER devices dramatically reduces injury rates for police officers and suspects. For more information about TASER technology, please call (800) 978-2737 or visit our website at www.taser.com.

Note to Investors

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements, without limitation, regarding our expectations, beliefs, intentions or strategies regarding the future. We intend that such forward-looking statements be subject to the safe-harbor provided by the Private Securities Litigation Reform Act of 1995. The forward-looking information is based upon current information and expectations regarding TASER International, Inc. These estimates and statements speak only as of the date on which they are made, are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. Such forward-looking statements relate to: expected revenue and earnings growth; estimations regarding the size of our target markets; successful penetration of the law enforcement market; expansion of product sales to the private security, military and consumer self-defense markets; growth expectations for new and existing accounts; expansion of production capability; new product introductions; product safety and our business model. We caution that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements herein.

TASER International assumes no obligation to update the information contained in this press release. These statements are qualified by important factors that could cause our actual results to differ materially from those reflected by the forward-looking statements. Such factors include but are not limited to: (1) market acceptance of our products; (2) our ability to establish and expand direct and indirect distribution channels; (3) our ability to attract and retain the endorsement of key opinion-leaders in the law enforcement community; (4) the level of product technology and price competition for our products; (5) the degree and rate of growth of the markets in which we compete and the accompanying demand for our products; (6) risks associated with rapid technological change and new product introductions; (7) competition; (8) litigation including lawsuits resulting from alleged product related injuries and death; (9) media publicity concerning allegations of deaths and injuries occurring after use of the TASER device and the negative effect this publicity could have on our sales; (10) TASER device tests and reports; (11) product quality; (12) implementation of manufacturing automation; (13) potential fluctuations in our quarterly operating results; (14) financial and budgetary constraints of prospects and customers; (15) potential delays in international and domestics orders; (16) dependence upon sole and limited source suppliers; (17) negative reports concerning the TASER device; (18) fluctuations in component pricing; (19) government regulations and inquiries; (20) dependence upon key employees and our ability to retain employees; (21) execution and implementation risks of new technology; (22) ramping manufacturing production to meet demand; (23) medical and safety studies; (24) field test results; and (25) other factors detailed in our filings with the Securities and Exchange Commission, including, without limitation, those factors detailed in the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.

For investor relations information please contact Katie Pyra by phone at 480-515-6330 or via email at $\underline{IR@TASER.com}$, or Dan Behrendt, Chief Financial Officer of TASER International, Inc., 480-905-2002.

TASER International, Inc. Consolidated Statements of Operations (Unaudited)

	For the Three Months Ended			
	Septe	ember 30, 2009	Septe	ember 30, 2008
Net Sales	\$	23,310,456	\$	22,859,459
Cost of Products Sold:				
Direct manufacturing expense		7,372,090		6,286,067
Indirect manufacturing expense		2,672,554		2,677,850
Total Cost of Products Sold		10,044,644		8,963,917
Gross Margin		13,265,812		13,895,542
Sales, general and administrative expenses		11,419,526		9,055,060
Research and development expenses		6,656,538		3,331,697
research and development expenses	-	0,030,330		3,331,077
Income (loss) from operations		(4,810,252)		1,508,785
Interest and other income, net		19,995		269,718
interest and other meome, net		17,775		207,710
Income (loss) before provision (benefit) for income taxes		(4,790,257)		1,778,503
Provision (benefit) for income taxes		(1,614,240)		1,128,126
Net income (loss)	\$	(3,176,017)	\$	650,377
The mediae (1988)	Ψ	(3,170,017)	Ψ	030,377
Income (loss) per common and common equivalent shares				
Basic	\$	(0.05)	\$	0.01
Diluted	\$	(0.05)	\$	0.01
Weighted average number of common and common equivalent shares				
outstanding				
Basic		61,937,769		61,714,889
Diluted		61,937,769		63,313,702

TASER International, Inc. Consolidated Statements of Operations (Unaudited)

Net Sales September 30, 2009 September 30, 2008 Net Sales \$ 69,748,635 \$ 66,447,272 Cost of Products Sold: \$ 20,081,221 19,877,521 Indirect manufacturing expense 8,033,623 6,306,617 Total Cost of Products Sold 28,114,844 26,184,138 Gross Margin 41,633,791 40,263,134 Sales, general and administrative expenses 33,689,688 27,925,704 Research and development expenses 15,246,764 8,463,231 Litigation judgment expense (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419 Net Loss \$ (4,367,179) (148,772)
Cost of Products Sold: Direct manufacturing expense 20,081,221 19,877,521 Indirect manufacturing expense 8,033,623 6,306,617 Total Cost of Products Sold 28,114,844 26,184,138 Gross Margin 41,633,791 40,263,134 Sales, general and administrative expenses 33,689,688 27,925,704 Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Cost of Products Sold: Direct manufacturing expense 20,081,221 19,877,521 Indirect manufacturing expense 8,033,623 6,306,617 Total Cost of Products Sold 28,114,844 26,184,138 Gross Margin 41,633,791 40,263,134 Sales, general and administrative expenses 33,689,688 27,925,704 Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Direct manufacturing expense 20,081,221 19,877,521 Indirect manufacturing expense 8,033,623 6,306,617 Total Cost of Products Sold 28,114,844 26,184,138 Gross Margin 41,633,791 40,263,134 Sales, general and administrative expenses 33,689,688 27,925,704 Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Direct manufacturing expense 20,081,221 19,877,521 Indirect manufacturing expense 8,033,623 6,306,617 Total Cost of Products Sold 28,114,844 26,184,138 Gross Margin 41,633,791 40,263,134 Sales, general and administrative expenses 33,689,688 27,925,704 Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Indirect manufacturing expense 8,033,623 6,306,617 Total Cost of Products Sold 28,114,844 26,184,138 Gross Margin 41,633,791 40,263,134 Sales, general and administrative expenses 33,689,688 27,925,704 Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Total Cost of Products Sold 28,114,844 26,184,138 Gross Margin 41,633,791 40,263,134 Sales, general and administrative expenses 33,689,688 27,925,704 Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Gross Margin 41,633,791 40,263,134 Sales, general and administrative expenses 33,689,688 27,925,704 Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Gross Margin 41,633,791 40,263,134 Sales, general and administrative expenses 33,689,688 27,925,704 Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Sales, general and administrative expenses 33,689,688 27,925,704 Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Sales, general and administrative expenses 33,689,688 27,925,704 Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Research and development expenses 15,246,764 8,463,231 Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Litigation judgment expense — 5,200,000 Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Loss from operations (7,302,661) (1,325,801) Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Interest and other income, net 162,044 1,492,448 Income (loss) before provision (benefit) for income taxes (7,140,617) Provision (benefit) for income taxes (2,773,438) 315,419
Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Income (loss) before provision (benefit) for income taxes (7,140,617) 166,647 Provision (benefit) for income taxes (2,773,438) 315,419
Provision (benefit) for income taxes (2,773,438) 315,419
Provision (benefit) for income taxes (2,773,438) 315,419
Net Loss <u>\$ (4,367,179)</u> <u>\$ (148,772)</u>
$\frac{\psi - (1,307,177)}{\psi - (1,0,772)}$
Loss per common and common equivalent shares
Basic \$ (0.07) \$ (0.00)
Diluted \$ (0.07) \$ (0.00)
Weighted average number of common and common equivalent shares
outstanding
Basic 61,891,638 62,568,846
Diluted 61,891,638 62,568,846

TASER International, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

		For the Three N	Month	s Ended	For the Nine Months Ended			s Ended
	Septe	ember 30, 2009	er 30, 2009 September 30, 2008		September 30, 2009		September 30, 2008	
GAAP net sales	\$	23,310,456	\$	22,859,459	\$	69,748,635	\$	66,447,272
Trade-in program revenue deferral		3,465,650				3,465,650		<u> </u>
Adjusted revenues	\$	26,776,106	\$	22,859,459	\$	73,214,285	\$	66,447,272
GAAP gross margin	\$	13,265,812	\$	13,895,542	\$	41,633,791	\$	40,263,134
Trade-in program revenue deferral		3,465,650		_		3,465,650		_
Adjusted gross margin	\$	16,731,462	\$	13,895,542	\$	45,099,441	\$	40,263,134
GAAP income (loss) from								
operations	\$	(4,810,252)	\$	1,508,785	\$	(7,302,661)	\$	(1,325,801)
Trade-in program revenue deferral		3,465,650		_		3,465,650		
Stock-based compensation expense (a)		1,022,863		665,259		3,782,181		1,396,116
Depreciation and amortization		923,722		646,775		2,408,539		1,945,526
Litigation judgment expense						<u> </u>		5,200,000
Adjusted operating income	\$	601,983	\$	2,820,819	\$	2,353,709	\$	7,215,841

a) Results include stock-based compensation as follows:

		For the Three N	Months Ended			For the Nine Months Ended			
	Septe	ember 30, 2009	Septe	ember 30, 2008	Sej	otember 30, 2009	Se	ptember 30, 2008	
Cost of Products Sold	\$	62,154	\$	72,370	\$	260,517	\$	182,838	
Sales, general and administrative	/e	,		,		,		,	
expenses		814,159		442,892		2,441,178		932,018	
Research and development									
expenses		146,550		149,997		1,080,486		281,260	
	\$	1,022,863	\$	665,259	\$	3,782,181	\$	1,396,116	

TASER International, Inc. Consolidated Balance Sheets (Unaudited)

September 30, 2009 December 31, 2008

ASSETS			
Current Assets			
Cash and cash equivalents	\$	45,414,569 \$	46,880,435
Short-term investments			2,498,998
Accounts receivable, net		16,318,653	16,793,553
Inventory		13,227,387	13,467,117
Prepaids and other assets		1,771,464	2,528,539
Current deferred income tax assets, net		9,430,073	9,430,073
Total current assets		86,162,146	91,598,715
Property and equipment, net		35,631,871	27,128,032
Deferred income tax assets, net		12,584,846	8,826,778
Intangible assets, net		2,624,384	2,447,011
Other long-term assets		116,245	14,970
Total Assets	\$	137,119,492 \$	130,015,506
LIABILITIES AND STOCKHO	OLDERS' EQUITY	•	
Current Liabilities			
Accounts payable	\$	7,704,600 \$	3,856,961
Accrued liabilities		3,847,560	4,275,907
Current deferred revenue		6,267,807	2,510,645
Customer deposits		293,510	312,686
Total Current Liabilities		18,113,477	10,956,199
Deferred revenue, net of current portion		4,821,519	4,840,965
Liability for unrecorded tax benefits		2,135,401	1,692,080
Total Liabilities		25,070,397	17,489,244
Commitments and Contingencies			
Stockholdow? Equity			
Stockholders' Equity Common stock		641	638
		91,553,138	87,663,129
Additional paid-in capital Treasury stock		(14,708,237)	(14,708,237)
Retained earnings		35,203,553	39,570,732
Total Stockholders' Equity		112,049,095	112,526,262
Total Liabilities and Stockholders' Equity	\$	137,119,492 \$	130,015,506

TASER International, Inc. Selected Consolidated Statement of Cash Flows Information (Unaudited)

	For the Nine Months Ended			
	September 30, 2009		September 30, 20	
Net loss	\$	(4,367,179)	\$	(148,772)
Depreciation and amortization		2,408,539		1,945,526
Stock-based compensation expense		3,782,181		1,396,113
Net cash provided by operating activities		5,461,095		4,611,061
Net cash (used) provided by investing activities		(7,034,792)		7,266,023
Net cash provided (used) by financing activities		107,831		(12,179,256)
Cash and cash equivalents, end of period	\$	45,414,569	\$	42,499,289